NCT07368764Active, not recruiting
The Suitability of Tience® for Treating Acne Scars
The Suitability of Tience® for the Treatment of Acne Scars
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
This is an open-label, single-center, split-face, pseudo-randomized clinical trial designed to evaluate the efficacy and safety of a human-derived, cell-free adipose tissue derivative (Tience® ), for treating moderate to severe acne scars. Participants will receive three treatment sessions over a three-month period: on Day 0, Day 30, and Day 90. Treatment will be administered via injections to acne-scarred areas on one side of the face. The untreated side will be treated after the follow-up period. Outcomes will be evaluated over a twelve-month period using investigator clinical assessments, patient self-evaluation and VISIA skin analysis system to monitor changes in scar severity and overall skin quality.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 20 Jan 2026
- Start date
- May 2025
- Primary completion date
- Aug 2026
- Lead sponsor
- Linio Biotech Oy
- NCT number
- NCT07368764
What you commit to
- Study type: Interventional
- Planned participants: 20
- From May 2025 to the primary completion date, Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- a strong medication used for treating severe acne (e.g., Isotretinoin)
- antihistamine medication (if the medication can be paused for 7 days during study visits, participation is possible)
- use of biological medications
- systemic medication affecting immunity
Other illness
- cancer or ongoing cancer treatment
- an active skin disease
- autoimmune disease
- known disease affecting blood clotting (bleeding or thrombosis tendency) (e.g., von Willebrand disease)
- are allergic to the product being studied or any of its ingredients
Other
- pregnancy or nursing
- Fitzpatric scale 4-6 skin type
- active acne or Herpes
- tendency for excessive scar formation
- tendency for urticaria (hives)
- smoke
Who the study is looking for
- \-
Age in the registry: 18 years to 40 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aava Kamppi Medical Centre Coordinator of this site? Confirm its status | Helsinki | Finland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.